# MOLN catalysts: MOLECULAR PARTNERS AG PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/moln/catalysts

> MOLECULAR PARTNERS AG (MOLN) has 1 upcoming catalyst. The next is the MP0712 interim data readout, 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, quarter only, year only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for MOLN?

MOLECULAR PARTNERS AG (MOLN) has 1 upcoming catalyst. The next is the MP0712 interim data readout, 2027. Press release filed with the SEC (EX-99): "Initial data anticipated within the coming months, comprehensive efficacy data expected in 2027" [Calendar and source filings](https://sec-api.dev/companies/moln/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001171843-26-004433, https://www.sec.gov/Archives/edgar/data/1745114/000117184326004433/exh_991.htm (retrieved 2026-11-12). Last confirmed 2026-07-07. Cite: https://sec-api.dev/companies/moln/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | MOLECULAR PARTNERS AG |
| Ticker | MOLN (Nasdaq) |
| SEC CIK | 1745114 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/moln |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jan 2023 | [MP0533 trial start](https://sec-api.dev/pdufa/mp0533) | MOLN | r/r AML and AML/MDS | completed | "In January 2023, the first patient was dosed in our Phase 1/2a clinical trial of MP0533 for patients with r/r AML and AML/MDS." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1745114/000174511426000009/moln-20251231.htm)) |
| Dec 2023 | [MP0533 interim data readout](https://sec-api.dev/pdufa/mp0533) | MOLN |  | completed, positive | "In December 2023, we presented positive initial data from the first four dosing cohorts at the 65th American Society of Hematology (ASH Annual Meeting and Exposition)." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1745114/000174511425000009/moln-20241231.htm)) |
| late 2025 | [MP0712 interim data readout](https://sec-api.dev/pdufa/mp0712) | MOLN |  | scheduled | "•IND filing and initial clinical data on first targeted Radio-DARPin therapy program, MP0712, expected in 2025; strategic partnership with Orano Med expanded from four to ten programs" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1745114/000174511425000020/secfinalprforq12025release.htm)) |
| Q4 2025 | [MOLECULAR PARTNERS AG interim data readout](https://sec-api.dev/companies/moln/catalysts) | MOLN |  | scheduled | "Cohort 9 is now fully recruited, with initial data expected to be presented in Q4 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1745114/000174511425000031/a20250825molecularpartners.htm)) |
| 2026 | [MP0726 interim data readout](https://sec-api.dev/pdufa/mp0726) | MOLN |  | scheduled | "Initial clinical data are expected in 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1745114/000174511425000031/a20250825molecularpartners.htm)) |
| Q1 2026 | [MP0712 trial start](https://sec-api.dev/pdufa/mp0712) | MOLN |  | scheduled | "A first site is open and dosing of the first patient is expected in Q1 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1745114/000117184326000214/exh_991.htm)) |
| 1H 2026 | [MP0712 interim data readout](https://sec-api.dev/pdufa/mp0712) | MOLN |  | scheduled | "With the data package complete, we anticipate the IND filing and Phase 1 initiation in 2025, and initial clinical data in H1 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1745114/000174511425000031/a20250825molecularpartners.htm)) |
| July 2, 2026 | [MP0712 trial start](https://sec-api.dev/pdufa/mp0712) | MOLN |  | completed | "Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1745114/000117184326004433/exh_991.htm)) |
| July 16, 2026 | [MP0317 trial start](https://sec-api.dev/pdufa/mp0317) | MOLN | advanced biliary tract carcinoma | completed | "53 LR - Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announces the dosing of first patients in an investigator-initiated Phase 2 proof-of-concept (POC) study of MP0317 in combination with chemoimmunotherapy in first line treatment for patients with advanced biliary tract carcinoma (TACTIC), also known as cholangiocarcinoma." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1745114/000117184326004758/exh_991.htm)) |
| 2027 | [MP0712 interim data readout](https://sec-api.dev/pdufa/mp0712) | MOLN |  | scheduled | "Initial data anticipated within the coming months, comprehensive efficacy data expected in 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1745114/000117184326004433/exh_991.htm)) |

## Drugs

- [MP0317](https://sec-api.dev/pdufa/mp0317): advanced cholangiocarcinoma, advanced biliary tract carcinoma
- [MP0533](https://sec-api.dev/pdufa/mp0533): r/r aml and aml/mds
- [MP0712](https://sec-api.dev/pdufa/mp0712): 
- [MP0726](https://sec-api.dev/pdufa/mp0726): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/moln/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "MOLN catalysts: MOLECULAR PARTNERS AG PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/moln/catalysts

```bibtex
@misc{secapidev_companies_moln_catalysts_20261116,
  title        = {MOLN catalysts: MOLECULAR PARTNERS AG PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/moln/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_moln_catalysts_20261116","title":"MOLN catalysts: MOLECULAR PARTNERS AG PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/moln/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
